Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy.

On-treatment cardiac events are not uncommon during adjuvant chemotherapy for early breast cancer. Higher dose of anthracyclines and higher body mass index are associated with a higher risk of on-treatment cardiac events.